Browse studies

Find your next paid study

1,252 recruiting studies matching your filters

Understanding Neural Mechanisms Underlying Visual Hallucinations in Lewy Body Diseases

The goal of this basic experimental study involving humans (BESH) protocol is to improve the understanding of neural mechanisms underlying visual hallucination…

Lewy Body DiseaseLewy Body DementiaParkinson Disease+2 more

Estimated

~$10 – $1,125

NYU Langone HealthNCT07849413

Phase 3

ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥ 50%.

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung …

Non-Small Cell Lung Cancer (NSCLC)

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT07361510

Phase 2

MC230716 Pilot Single-Arm, Pragmatic Trial Of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access And Remote Expertise) Beyond Walls (CCBW) Program

This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. …

Advanced Esophageal Squamous Cell CarcinomaAdvanced Renal Cell CarcinomaClinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8+28 more

Phase 1

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Advanced Solid Tumors

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects…

NSCLC (Non-small Cell Lung Cancer)HNSCCEndometrial+5 more

Estimated

~$10 – $8,750

TwoStep Therapeutics, Inc.NCT07814248

Phase 2

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with …

Non Small Cell Lung Cancer

Estimated

~$10 – $8,750

Shanghai Henlius BiotechNCT06907615

Remote eligible

Natural History and Genetics of Food Allergy and Related Conditions

Background: \- About 15 million Americans have a food allergy. Because there are no cures or effective prevention or treatment for food allergies, researchers…

Food AllergyLoeys-Dietz SyndromeAtopic Dermatitis+1 more

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT02504853

Phase 3

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that …

Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell Carcinoma+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04181060

Studies on Thyroid Nodules and Thyroid Cancer

Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer. The main purpose of this study is to furth…

Hurthle Cell Thyroid CancerTall Cell Variant Thyroid CancerFollicular Thyroid Cancer+2 more

Estimated

~$10 – $675

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00001160

Phase 1

Phase I Dose Escalation Study of Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-cell Acute Lymphoblastic Leukemia (B-ALL)

Background: B-cell acute lymphoblastic leukemia (B-ALL) is a type of blood cancer. Some people with B-ALL have a gene mutation that makes the disease hard to …

B-AllAcute Lymphoblastic Leukemia

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07572136

Observational

Targeting the Hip Abductors to Reduce Falls in Older Veterans Through A Virtual Multimodal Balance Intervention

Falls are a major health concern and a leading cause of injurious death and non-fatal injuries in older Veterans who are at greater risk for falls than non-Vet…

Falls

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT07109466

Phase 2

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chem…

Non Small Cell Lung Cancer (Squamous or Non Squamous)Stage 4 NSCLC

Estimated

~$10 – $8,750

Eikon TherapeuticsNCT07365319

Observational

Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis

This study is designed to evaluate the efficacy, safety, and tolerability of PL-14 Allergy Blocker compared to saline spray in adults with Seasonal Allergic Rh…

Seasonal Allergic Rhinitis (SAR)Allergic Rhinitis

Estimated

~$10 – $8,750

Polyrizon Ltd.NCT07588672